Keryx Biopharmaceuticals Inc (KERX) financial statements (2021 and earlier)

Company profile

Business Address ONE MARINA PARK DR.
BOSTON, MA 02210
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

9/30/2018
Q3
6/30/2018
Q2
3/31/2018
Q1
12/31/2017
Q4
9/30/2017
Q3
6/30/2017
Q2
3/31/2017
Q1
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments4149609411414191
Cash and cash equivalents4149609411414191
Receivables1515138986
Inventory, net of allowances, customer advances and progress billings59493529261813
Inventory59493529261813
Other current assets1212111116910
Total current assets:126126120142165176119
Noncurrent Assets
Property, plant and equipment4445544
Intangible assets, net (including goodwill)3333333
Goodwill3333333
Other noncurrent assets18131310111
Total noncurrent assets:25202117988
TOTAL ASSETS:152146140159174184128
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:57554545373022
Accounts payable151811678 
Accrued liabilities32312922870
Employee-related liabilities663866 
Other undisclosed accounts payable and accrued liabilities3119151022
Other liabilities0000000
Other undisclosed current liabilities0000000
Total current liabilities:57554545373122
Noncurrent Liabilities
Long-term debt and lease obligation147130125125125125125
Long-term debt, excluding current maturities147130125125125125125
Liabilities, other than long-term debt2222222
Deferred revenue and credits1111111
Other liabilities1111111
Other undisclosed noncurrent liabilities   1111
Total noncurrent liabilities:149132127128128128128
Total liabilities:206187172173165159150
Stockholders' equity
Stockholders' equity attributable to parent(54)(41)(32)(14)926(23)
Common stock0000000
Treasury stock, value(0)(0)(0)(0)(0)(0)(0)
Additional paid in capital1,0041,000988985977970836
Accumulated deficit(1,058)(1,041)(1,020)(999)(968)(945)(858)
Total stockholders' equity:(54)(41)(32)(14)926(23)
TOTAL LIABILITIES AND EQUITY:152146140159174184128

Income statement (P&L) ($ in millions)

9/30/2018
Q3
6/30/2018
Q2
3/31/2018
Q1
12/31/2017
Q4
9/30/2017
Q3
6/30/2017
Q2
3/31/2017
Q1
Revenues28262219151512
Revenue, net262219151512
Cost of revenue
(Cost of Goods and Services Sold)
(2)(1)(4)(2)(6)(4)(0)
Gross profit:2625181791112
Operating expenses(43)(46)(45)(50)(39)(39)(35)
Other undisclosed operating income2142640
Operating loss:(15)(20)(23)(31)(24)(24)(23)
Nonoperating income (expense)(2)(1)000(63)0
Investment income, nonoperating   1   
Other nonoperating income (expense)(0)(0)00000
Interest and debt expense(0)(1)   (63) 
Other undisclosed income from continuing operations before equity method investments, income taxes01   63 
Loss from continuing operations before income taxes:(17)(22)(23)(31)(23)(86)(23)
Income tax expense (benefit)  10(0)(0)(0)
Net loss available to common stockholders, diluted:(17)(22)(22)(30)(23)(86)(23)

Comprehensive Income ($ in millions)

9/30/2018
Q3
6/30/2018
Q2
3/31/2018
Q1
12/31/2017
Q4
9/30/2017
Q3
6/30/2017
Q2
3/31/2017
Q1
Net loss:(17)(22)(22)(30)(23)(86)(23)
Comprehensive loss, net of tax, attributable to parent:(17)(22)(22)(30)(23)(86)(23)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: